Moffitt Cancer Center’s Phase 3 Study May Be Game-Changer for Acute Myeloid Leukemia

Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation.

“Acute myeloid leukemia is an aggressive blood cancer with very low rates of treatment success, especially in older patients,” explained Jeffrey Lancet, M.D., senior member of the Department of Malignant Hematology and chief of the Leukemia Section at Moffitt.